The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer

Monday, July 28, 2014 Pages: 1658-1672 DOI: 10.3892/ijo.2014.2565

Involvement of substance P and the NK-1 receptor in pancreatic cancer

World J Gastroenterol. 2014 Mar 7; 20(9): 2321–2334.
Published online 2014 Mar 7. doi:  10.3748/wjg.v20.i9.2321

Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo

Journal of Hepatology Volume 60, Issue 5, May 2014, Pages 985–994

Involvement of substance P and the NK-1 receptor in cancer progression

Peptides 48 (2013) 1– 9

Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts

Tuesday, November 5, 2013 Pages: 137-146 DOI: 10.3892/ijo.2013.2164

The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists

NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011

July 2012, Vol. 22, No. 7 , Pages 735-746 (doi:10.1517/13543776.2012.697153)

NK-1 Receptor Antagonists: A New Generation of Anticancer Drug

ISSN (Print): 1389-5575 ISSN (Online): 1875-5607 VOLUME: 12 ISSUE: 7 DOI: 10.2174/138955712800626692 

The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines

Investigational New Drugs April 2012, Volume 30, Issue 2,pp 529-540

A Therapeutic Target in Leukemia: The NK-1 Receptor

ISBN 978-1-61470-872-8

The role of Neurokinin-1 receptor in the microenvironment of inflammation and cancer

Doi: 10.1100/2012/381434

NK-1 receptor as a melanoma target

ISSN: 1744-7631 Doi: 10.1517/14728222.2011.586633.

NK-1 receptor antagonists: a new paradigm in pharmacological therapy

ISSN (Print): 0929-8673 ISSN (Online): 1875-533X DOI: 10.2174/092986711795496746

The NK-1 Receptor: A New Target in Cancer Therapy

ISSN (Print): 1389-4501 ISSN (Online): 1873-5592 DOI: 10.2174/138945011795528796

NK-1 receptor: a new promising target in treatment of cancer

Discovery Medicine; ISSN: 1539-6509; Discov Med 10(53):305-313, October 2010.

Neurokinin-1 receptor antagonists: a comprehensive patent survey

August 2010, Vol. 20, No. 8 , Pages 1019-1045 (doi:10.1517/13543776.2010.495121)

The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile

Doi:10.1016/j.peptides.2010.06.002

The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines

Laboratory Investigation (2010) 90, 1259–1269; doi:10.1038/labinvest.2010.92; published online 10 May 2010

Immunolocalization of NK-1 receptor and substance P in human normal placenta

Placenta 31 (2010) 649e651

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

Invest New Drugs (2010) 28:187–193 DOI 10.1007/s10637-009-9218-8

A new frontier in the treatment of cancer: NK-1 receptor antagonists

Volume 17, Number 6, February 2010, pp.504-516(13)

Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence

Breast Cancer Research and Treatment July 2010, Volume 122, Issue 2, pp 601-603

The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines

Cancers 2010, 2(2), 611-623; Doi:10.3390/cancers2020611

A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma

Anticancer Research June 2009 vol. 29 no. 62323-2329

Expression of Substance P and Neurokinin-1-receptor in Laryngeal Cancer: Linking Chronic Inflammation to Cancer Promotion and Progression

DOI: 10.1111/j.1365-2559.2008.03193.x

A role for the substance P/NK-1 receptor complex in cell proliferation and apoptosis in oral lichen planus

Oral Diseases Volume 15, Issue 2, pages 162–169, March 2009 DOI: 10.1111/j.1601-0825.2008.01504.x

Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours

Oral Oncology Volume 44, Issue 12, December 2008, Pages 1127–1133

The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines

Published: Tumor Biology. 2008; 29: 245-254. Doi: 10.1159/000152942. Epub 2008 Sep 9.

Immunolocalization of the Neurokinin-1 receptor: a new target in the treatment of the human primary retinoblastoma

Focus on Eye Neoplasma Research Progress. Bospene E.B. (ed.) Nova Science Publishers, New York 2008; pp. 157-178.

NK-1 receptor antagonists induce apoptosis and counteract substance p-related mitogenesis in human laryngeal cancer cell line HEp-2

29 September 2007 Springer Science + Business Media, LLC 2007

Neurokinin-1 receptor antagonists and cancer

Focus on Neuropeptide Research, 2007: 341-362 ISBN: 978-81-7895-291-8

Neuropeptides and cancer: focus on substance P/neurokinin-1 receptor system research

Neuropeptides Research Trends. Bernice A. Levine (ed.) Nova Science Publishers, New York 2007; pp. 97-119.

NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines

ISBN: 1-60021-484-3

The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines

Letters in Drug Design & Discovery, Volume 3, Number 5, July 2006, pp. 323-329(7)

Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines

Doi: 10.1167/iovs.05-1591Invest. Ophthalmol. Vis. Sci.June 2007 vol. 48 no. 62775-2781

Neurokinin-1 Receptors Located in Human Retinoblastoma Cell Lines: Antitumor Action of Its Antagonist, L-732,138

Doi: 10.1167/iovs.05-1591Invest. Ophthalmol. Vis. Sci.June 2007 vol. 48 no. 62775-2781

A role for Substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage

Cancer and Metastasis Review 2006; 25:137-145.

The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines

Neuropeptides. 2005 Aug;39(4):427-32.

Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines

Melanoma Res. 2004 Jun;14(3):183-8.

Antitumoral Action of the Neurokinin-1-Receptor Antagonist L-733,060 and Mitogenic Action of Substance P on Human Retinoblastoma Cell Lines

Doi: 10.1167/iovs.04-1530 Invest. Ophthalmol. Vis. Sci. July 2005 vol. 46 no. 7 2567-2570

Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines

Vol. 142, No. 2